EGF and myopic macular degeneration: In the clinical study as a phase-1 trial, the adult highly myopic patients had received the intravitreal panitumumab injections based on the hypothesis, that adult highly myopic eyes can undergo further axial elongation, that such an axial elongation is a major risk factor for deterioration of myopic macular degeneration, and that the myopic axial elongation is related to a retina-triggered, EGF-induced and RPE-mediated growth of Bruch ́s membrane in the midperiphery of the fundus [18,23].